Tailoring the dendronized structures of cyclodextrin-based supramolecular nanoassemblies for enhanced tumor paraptosis via disrupting endoplasmic reticulum homeostasis
Source abstract
Abstract
Bioactive nanomaterials have been extensively utilized in medical applications. There are, however, very few reports on clinical applications of methylated β-cyclodextrin-derived supramolecular bioactive nanoagents, particularly in relation to the chemical features and biological properties. Herein, we designed and fabricated supramolecular bioactive nanoassemblies derived from permethyl β-cyclodextrin (PMCD) with increased proportions of PMCD on their dendronized side chains and further investigated the impact of chemical structures on their antitumor efficacy. Importantly, enhanced antitumor efficacy was observed with an increase in the proportion of PMCD on the dendronized side chains. Notably, pHPMA-co-(dendron Permethyl-β-CD4) (P4), which was featured with the highest PMCD proportion on its side chains, demonstrated the greatest potency in disrupting endoplasmic reticulum (ER) homeostasis, thus achieving conspicuous tumor cell paraptosis and promising antitumor efficacy in vivo without obvious side effects. Mechanistically, P4 colocalized with the ER, disrupted ER homeostasis, and triggered ER stress through the upregulation of proteins associated with the unfolded protein response, thus provoking abundant cytoplasmic vacuoles through the dilation of ER and resultant tumor paraptosis, a non-apoptotic mode of cell death. Overall, this study lays the groundwork for the precise design and synthesis of supramolecular bioactive agents derived from methylated β-cyclodextrin by precisely modulating their chemical structures. STATEMENT OF SIGNIFICANCE: Cyclodextrin-based supramolecular bioactive nanoagents could be employed for tumor management. However, there are challenges in developing β-cyclodextrin-derived bioactive nanoagents and tuning their structure-activity relationship to enhance their antitumor effects. Herein, we synthesized several bioactive nanoagents utilizing HPMA and PMCD by meticulously modulating their dendronized structures. It was revealed that P4, which was featured with the highest proportion of PMCD on its side chains, could distinctly interact with the ER. This enhanced interaction disrupted ER homeostasis, resulting in pronounced ER stress and paraptosis in tumor cells. Additionally, P4 exhibited efficient tumor retention and effective antitumor activity in vivo. This study demonstrated that biological function of β-cyclodextrin-derived bioactive nanoagents could be enhanced through optimization of the PMCD proportion on their side chains.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Autophagy in Disease and Therapy · Endoplasmic Reticulum Stress and Disease · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Bioactive inorganic nanomaterials for cancer theranostics10.1039/D2CS00352J ↗
2. Nanomaterials for engineering stem cell responses10.1002/adhm.201500272 ↗
3. Advances and applications of nanoparticles in cancer therapy
4. Metformin-based nanomedicines for reprogramming tumor immune microenvironment10.7150/thno.104872 ↗
5. Bioactive vanadium disulfide nanostructure with "dual" antitumor effects of vanadate and gas for Immune-checkpoint blockade-enhanced cancer Immunotherapy10.1021/acsnano.3c04767 ↗
6. Multicomponent self-assembly of a giant heterometallic polyoxotungstate supercluster with antitumor activity10.1002/anie.202017318 ↗
7. Biomarker-driven molecular imaging probes in radiotherapy10.7150/thno.97768 ↗
8. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy10.1038/nnano.2017.69 ↗
9. An antibody-like polymeric nanoparticle removes intratumoral Galectin-1 to enhance antitumor T-cell responses in cancer immunotherapy10.1021/acsami.1c02116 ↗
10. Co-assembly of polymeric conjugates sensitizes neoadjuvant chemotherapy of triple-negative breast cancer with reduced systemic toxicity10.1016/j.actbio.2023.12.026 ↗
11. Polymer vesicles as nanoreactors for biomedical applications10.1016/j.preme.2024.100004 ↗
12. Carbon quantum dots-based nanozyme from coffee induces cancer cell ferroptosis to activate antitumor immunity10.1021/acsnano.2c01619 ↗
13. A mild hyperthermia hollow carbon nanozyme as pyroptosis inducer for boosted antitumor immunity10.1021/acsnano.3c07601 ↗
14. Enantiomeric virus-inspired oncolytic particles for efficient antitumor immunotherapy10.1021/acsnano.3c05288 ↗
15. Copper-induced supramolecular peptide assemblies for multi-pathway cell death and tumor inhibition
16. Photobleaching-mediated charge-convertible cyclodextrin nanoparticles achieve deep tumour penetration for rectal cancer theranostics10.1038/s41565-024-01757-4 ↗
17. Stimulus-responsive polysaccharide-based hydrogels: from design to biomedical applications10.1016/j.preme.2024.100001 ↗
18. Spatiotemporal control of cell–cell reversible interactions using molecular engineering10.1038/ncomms13088 ↗
19. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy
20. Involvement of cholesterol depletion from lipid rafts in apoptosis induced by methyl-β-cyclodextrin10.1016/j.ijpharm.2013.04.071 ↗
21. Cholesterol depletion by methyl-β-cyclodextrin augments tamoxifen induced cell death by enhancing its uptake in melanoma10.1186/1476-4598-13-204 ↗
22. Involvement of PI3K-Akt-Bad pathway in apoptosis induced by 2,6-di-O-methyl-β-cyclodextrin, not 2,6-di-O-methyl-α-cyclodextrin, through cholesterol depletion from lipid rafts on plasma membranes in cells10.1016/j.ejps.2009.07.010 ↗
23. Advanced bioactive nanomaterials for biomedical applications10.1002/EXP.20210089 ↗
24. A transistor-like pH-sensitive nanodetergent for selective cancer therapy10.1038/s41565-022-01085-5 ↗
25. Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress10.1038/s43018-022-00389-8 ↗
26. Homomultivalent polymeric nanotraps disturb lipid metabolism homeostasis and tune pyroptosis in cancer10.1002/adma.202312528 ↗
27. Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells10.1016/j.apsb.2024.03.010 ↗
28. Branched glycopolymer prodrug-derived nanoassembly combined with a STING agonist activates an immuno-supportive status to boost anti-PD-L1 antibody therapy10.1016/j.apsb.2024.02.006 ↗
29. Dual stimuli-responsive dendronized prodrug derived from poly(oligo-(ethylene glycol) methacrylate)-based copolymers for enhanced anti-cancer therapeutic effect10.1016/j.actbio.2022.02.033 ↗
30. The ‘visualized’ macrocycles: chemistry and application of fluorophore tagged cyclodextrins10.1016/j.ijpharm.2017.04.035 ↗
31. Jie · Chem. Soc. Rev. · 2015 · 44 · 356810.1039/C4CS00390J ↗
32. The antitumor effects of methyl-β-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts10.1016/j.bbrc.2014.11.006 ↗
33. Antiproliferative effect of methyl-β-cyclodextrin in vitro and in human tumour xenografted athymic nude mice10.1038/bjc.1998.648 ↗
34. Small-molecule compounds target paraptosis to improve cancer therapy10.1016/j.biopha.2019.109203 ↗
35. Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation10.1038/s41392-022-01131-7 ↗
36. Gambogic acid triggers vacuolization-associated cell death in cancer cells via disruption of thiol proteostasis10.1038/s41419-019-1360-4 ↗
37. Honokiol induces paraptosis-like cell death of acute promyelocytic leukemia via mTOR & MAPK signaling pathways activation10.1007/s10495-020-01655-9 ↗
38. Paraptosis: mediation by MAP kinases and inhibition by AIP-1/Alix10.1038/sj.cdd.4401465 ↗
39. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective10.1016/j.ebiom.2024.105301 ↗
40. Tumor-targeting drug delivery regimens based on vascular disrupting agents10.1016/j.preme.2024.100003 ↗